Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
PROCTER & GAMBLE HEALTH ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
PROCTER & GAMBLE HEALTH Jun-23 |
ADCOCK INGRAM Jun-14 |
PROCTER & GAMBLE HEALTH/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 5,366 | 320 | - | |
Low | Rs | 3,883 | 231 | - | |
Sales per share (Unadj.) | Rs | 740.7 | 95.3 | - | |
Earnings per share (Unadj.) | Rs | 138.2 | -24.0 | - | |
Cash flow per share (Unadj.) | Rs | 155.2 | -19.9 | - | |
Dividends per share (Unadj.) | Rs | 95.00 | 0 | - | |
Avg Dividend yield | % | 2.1 | 0 | - | |
Book value per share (Unadj.) | Rs | 447.6 | 74.8 | - | |
Shares outstanding (eoy) | m | 16.60 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 6.2 | 2.9 | 215.8% | |
Avg P/E ratio | x | 33.5 | -11.5 | -291.3% | |
P/CF ratio (eoy) | x | 29.8 | -13.9 | -215.1% | |
Price / Book Value ratio | x | 10.3 | 3.7 | 280.2% | |
Dividend payout | % | 68.7 | 0 | - | |
Avg Mkt Cap | Rs m | 76,761 | 46,551 | 164.9% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 2,062 | 2,922 | 70.6% | |
Avg. sales/employee | Rs Th | 0 | 3,747.7 | - | |
Avg. wages/employee | Rs Th | 0 | 680.6 | - | |
Avg. net profit/employee | Rs Th | 0 | -944.3 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 12,296 | 16,089 | 76.4% | |
Other income | Rs m | 184 | 113 | 163.2% | |
Total revenues | Rs m | 12,480 | 16,201 | 77.0% | |
Gross profit | Rs m | 3,247 | -2,788 | -116.5% | |
Depreciation | Rs m | 281 | 694 | 40.5% | |
Interest | Rs m | 8 | 436 | 1.8% | |
Profit before tax | Rs m | 3,142 | -3,806 | -82.6% | |
Minority Interest | Rs m | 0 | -11 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 847 | 238 | 356.3% | |
Profit after tax | Rs m | 2,295 | -4,054 | -56.6% | |
Gross profit margin | % | 26.4 | -17.3 | -152.4% | |
Effective tax rate | % | 27.0 | -6.2 | -431.6% | |
Net profit margin | % | 18.7 | -25.2 | -74.1% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 11,713 | 11,784 | 99.4% | |
Current liabilities | Rs m | 6,791 | 6,630 | 102.4% | |
Net working cap to sales | % | 40.0 | 32.0 | 125.0% | |
Current ratio | x | 1.7 | 1.8 | 97.0% | |
Inventory Days | Days | 263 | 111 | 236.9% | |
Debtors Days | Days | 343 | 124 | 277.1% | |
Net fixed assets | Rs m | 10,617 | 6,869 | 154.6% | |
Share capital | Rs m | 166 | 75 | 222.2% | |
Net worth | Rs m | 7,431 | 12,628 | 58.8% | |
Long term debt | Rs m | 0 | 4,438 | 0.0% | |
Total assets | Rs m | 22,330 | 23,855 | 93.6% | |
Interest coverage | x | 409.1 | -7.7 | -5,290.2% | |
Debt to equity ratio | x | 0 | 0.4 | 0.0% | |
Sales to assets ratio | x | 0.6 | 0.7 | 81.6% | |
Return on assets | % | 10.3 | -15.2 | -68.0% | |
Return on equity | % | 30.9 | -32.1 | -96.2% | |
Return on capital | % | 42.4 | -19.8 | -214.0% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 2,360 | 1,373 | 171.8% | |
From Investments | Rs m | -215 | -422 | 51.0% | |
From Financial Activity | Rs m | -985 | 4,028 | -24.4% | |
Net Cashflow | Rs m | 1,160 | 4,979 | 23.3% |
Compare PROCTER & GAMBLE HEALTH With: MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Compare PROCTER & GAMBLE HEALTH With: SEQUENT SCIENTIFIC SMRUTHI ORGANICS PANACEA BIOTECH UNICHEM LAB AAREY DRUGS
Asian shares slipped before a Bank of Japan policy decision where authorities are likely to bring an end to the world's last negative rates regime.